Literature DB >> 36245815

Angiotensin converting enzyme inhibitors from medicinal plants: a molecular docking and dynamic simulation approach.

Olumide Samuel Fadahunsi1, Olubukola Sinbad Olorunnisola1, Peter Ifeoluwa Adegbola1,2, Temitayo I Subair2, Oluwabamise Emmanuel Elegbeleye1.   

Abstract

Angiotensin converting enzyme (ACE) is a key enzyme and mediator in the aetiology of high blood pressure (HBP) and hypertension. As one of the leading cause of untimely death worldwide, there is a lot of research and studies on the management and treatment of hypertension. The usage of medicinal plants in the management of hypertension as alternative to synthetic allopathic drugs is a common practice in folkloric and traditional medicine. Therefore, this study was aimed to investigate the ACE inhibitory activity of some medicinal plants which are commonly used in the treatment of HBP in southwestern part of Nigeria using extensive in-silico approach. Compounds identified in the plants through GC-MS technique, together with Lisinopril were docked against ACE protein. It was observed that only 40 of the compounds had binding affinity ≥ - 6.8 kcal/mol which was demonstrated by the standard drug (lisinopril). Interaction between the compounds and ACE was via conventional hydrogen, carbon hydrogen, alkyl, pi-alkyl, pi-carbon, and Van Der Wall bonds among others. Most of these compounds exhibited drug like properties, without violating majority of the physicochemical descriptors and Lipinski rule of 5. The ADMET evaluation revealed that only 2 compounds (cyclopentadecanone and oxacycloheptadecan-2-one) which were identified in Bacopa florinbunda plant were predicted non-toxic and thus were subjected to molecular dynamics and simulation with ACE. From the molecular dynamics and mechanics analysis, both cyclopentadecanone and oxacycloheptadecan-2-one showed high stability and inhibitory potentials when bound to ACE. Oxacycloheptadecan-2-one was more stable than lisinopril and cyclopentadecanone in the ligand-ACE complex; we therefore suggested its experimental and clinical validation as drug candidates for the treatment of hypertension. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-022-00135-z.
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Entities:  

Keywords:  Angiotensin converting enzyme (ACE) inhibitors; Dynamics; Hypertension; In-silico; Medicinal plants; Molecular docking; Simulation

Year:  2022        PMID: 36245815      PMCID: PMC9561457          DOI: 10.1007/s40203-022-00135-z

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  54 in total

1.  Arg(1098) is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity.

Authors:  X Liu; M Fernandez; M A Wouters; S Heyberger; A Husain
Journal:  J Biol Chem       Date:  2001-06-29       Impact factor: 5.157

Review 2.  Adipocyte dysfunction, inflammation and metabolic syndrome.

Authors:  Nora Klöting; Matthias Blüher
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

Review 3.  Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

Authors:  Franz H Messerli; Sripal Bangalore; Chirag Bavishi; Stefano F Rimoldi
Journal:  J Am Coll Cardiol       Date:  2018-04-03       Impact factor: 24.094

4.  The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).

Authors:  Jeffrey D Coleman; K Sandeep Prabhu; Jerry T Thompson; P Sreenivasula Reddy; Jeffrey M Peters; Blake R Peterson; C Channa Reddy; John P Vanden Heuvel
Journal:  Free Radic Biol Med       Date:  2007-01-08       Impact factor: 7.376

Review 5.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

6.  Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System.

Authors:  Wang Wang; Shaun M K McKinnie; Maikel Farhan; Manish Paul; Tyler McDonald; Brent McLean; Catherine Llorens-Cortes; Saugata Hazra; Allan G Murray; John C Vederas; Gavin Y Oudit
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

7.  Three Novel ACE Inhibitory Peptides Isolated From Ginkgo biloba Seeds: Purification, Inhibitory Kinetic and Mechanism.

Authors:  Fei-Fei Ma; Hao Wang; Chao-Kun Wei; Kiran Thakur; Zhao-Jun Wei; Li Jiang
Journal:  Front Pharmacol       Date:  2019-01-15       Impact factor: 5.810

8.  Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting.

Authors:  Thierry Hanser; Fabian P Steinmetz; Jeffrey Plante; Friedrich Rippmann; Mireille Krier
Journal:  J Cheminform       Date:  2019-02-02       Impact factor: 5.514

9.  A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.

Authors:  Ahmed Rakib; Zulkar Nain; Saad Ahmed Sami; Shafi Mahmud; Ashiqul Islam; Shahriar Ahmed; Adnan Bin Faisul Siddiqui; S M Omar Faruque Babu; Payar Hossain; Asif Shahriar; Firzan Nainu; Talha Bin Emran; Jesus Simal-Gandara
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 13.994

10.  Microbial Mutagenicity Assay: Ames Test.

Authors:  Urvashi Vijay; Sonal Gupta; Priyanka Mathur; Prashanth Suravajhala; Pradeep Bhatnagar
Journal:  Bio Protoc       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.